China’s Biopharma Homecoming
September 1, 2026
Chinese biopharma leaders are returning from the West to build a more confident – and innovative – global industry, says Cyagen’s Lance Han
7 min read
False
The voices driving change and progress in medicine making. Explore stories, interviews, and community highlights that inspire and inform.
Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania Perelman School of Medicine
View Profile
Claudia Zylberberg discusses building the infrastructure, partnerships, and policies needed to bring advanced therapies to patients at scale
All the latest Medicine Maker articles.
August 26, 2026
Jon Rees sees signs of recovery following biotech's post-pandemic funding reset, but there’s no going back to the “old normal”
9 min read
August 26, 2026
Merck and Moderna report positive phase III results for intismeran in melanoma, as The Medicine Maker revisits how cancer vaccines work and the challenges still facing the field
7 min read
August 25, 2026
Reliable discovery insights depend on models grounded in curated, verifiable scientific knowledge
5 min read
August 24, 2026
A new preservation method could remove a major barrier to treatment, the FDA approves the first gene therapy for GSDIa, and ultrasound directs CAR T cells toward solid tumors
5 min read
August 24, 2026
Members of the 2026 Power List argue that manufacturing, infrastructure, reimbursement, and investment now pose the greatest challenges
9 min read
August 21, 2026
Former military intelligence officer Tony Page discusses what pharma can learn from early warning systems, decision cycles, and the discipline of intelligence
5 min read
August 20, 2026
From multiple sclerosis to AI-driven discovery, Daniel Vitt reflects on the future of drug development
6 min read
August 19, 2026
Can iPSC platforms deliver consistent, commercial-scale cell therapies for large patient populations?
5 min read
August 18, 2026
From collapsing legacy models to the rise of Chinese biotech, industry leaders are being forced to rethink how drugs are developed, funded, and brought to market
10 min read
August 17, 2026
PRAME-targeted T cells produce a complete response in metastatic nephroblastoma, CAR T cells remain active after a decade, and an in vivo CRISPR screen identifies edits that strengthen solid-tumor activity
3 min read
False